Nippon Shinyaku

Basic Information

Stock Code
4516
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Kyoto Prefecture
Establishment Year
October 1919
Listing Year
March 1956
Official Website
https://www.nippon-shinyaku.co.jp/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Kyowa Kirin, Takeda Pharmaceutical, Astellas Pharma, Shionogi, Chugai Pharmaceutical, Kaken Pharmaceutical, Eisai, Ono Pharmaceutical, Santen Pharmaceutical, Zeria Pharmaceutical, Daiichi Sankyo, Otsuka Holdings

Overview

Nippon Shinyaku is a pharmaceutical manufacturer founded in 1919 and based in Kyoto, with strengths in the urology and hematologic oncology fields, and focusing on research and development of nucleic acid drugs.

Current Situation

Nippon Shinyaku recorded consolidated net sales of approximately 148.2 billion yen, operating income of approximately 33.3 billion yen, and net assets of approximately 220.5 billion yen for the fiscal year ending March 2024, maintaining a stable financial base. It retains competitiveness in the domestic market through the manufacture and sale of mainstay urological drugs and hematology drugs, while strengthening research and development of nucleic acid drugs. It is advancing global expansion with bases in the United States, China, and the UK. It promotes sustainability, contributing to healthcare and environmental conservation. In the medium to long term, it aims for growth through strengthened research and development and expansion of drugs for rare diseases. It is actively investing in new businesses and focusing on developing innovative pharmaceuticals.

Trivia

Interesting Facts

  • Long-established pharmaceutical company founded in 1919
  • Specializes in urological drugs and highly evaluated in the industry
  • Holding Nippon Shinyaku Children's Literature Award since 2009
  • Drum explosion accident occurred but no legal issues
  • Owns multiple research labs and factories in Kyoto
  • Leading-edge company focusing on nucleic acid drug development
  • Related companies include food and overseas pharmaceutical firms
  • Hardball baseball team is a regular at Urban vs. National Baseball Tournament
  • Chairman and President hold distinct roles
  • Major shareholders include many trust banks and life insurance companies

Hidden Connections

  • Many financial institutions as major shareholders support capital and management stability
  • Collaborative relationships with health food manufacturers in functional foods
  • Overseas bases strategically positioned directly linked to major markets
  • Diversified into formulation technology and food sectors through subsidiaries
  • Collaborates with domestic and international research institutions on nucleic acid drug R&D
  • Nippon Shinyaku hardball baseball team has produced many professional baseball players
  • Founder inherits tradition from Kyoto Shinyaku-do
  • Characteristic position competing with and collaborating with major pharmaceutical companies

Future Outlook

Growth Drivers

  • Nucleic acid drug market expansion and technological innovation
  • Increasing demand for rare disease drugs
  • Growth in functional food market
  • Expansion of pharmaceutical sales domestically and internationally
  • New drug creation through strengthened R&D capabilities
  • Efficiency improvements through digital technology utilization
  • Strategic expansion of overseas bases
  • Response to diversifying medical needs
  • Support from government healthcare and health policies
  • Strengthening pharmaceutical safety and quality

Strategic Goals

  • Accelerating new drug creation centered on nucleic acid drugs
  • Increasing overseas sales ratio to over 40%
  • Strengthening lineup of rare disease treatments
  • Full-scale expansion of functional food business
  • Achieving sustainability goals and fulfilling social responsibilities
  • Efficient management through integration of pharmaceutical technology and DX
  • Enhancing brand value in global markets
  • Advanced quality control and safety measures
  • Strengthening employee expertise and diversity
  • Promoting symbiotic activities with local communities

Business Segments

Medical Pharmaceutical Provision

Overview
Stably supplies high-quality pharmaceuticals to medical institutions.
Competitiveness
High research and development capabilities specialized in specific fields
Customers
  • Hospitals
  • Clinics
  • Dispensing Pharmacies
  • Medical Wholesalers
  • Pharmaceutical Distributors
Products
  • Urological Drugs
  • Hematology Treatments
  • Rare Disease Drugs
  • Primary Care Drugs

Functional Food Manufacturing and Sales

Overview
Provides products that support health promotion to consumers.
Competitiveness
Product development based on scientific evidence of safety and efficacy
Customers
  • Health Food Retailers
  • Online Stores
  • Drugstores
  • Nutritional Supplement Wholesalers
Products
  • Functional Labeled Foods
  • Health Supplements
  • Nutritional Supplements

Drug Discovery Research and Technology Provision

Overview
Provides drug discovery support services using cutting-edge technology.
Competitiveness
Advanced technological capabilities in nucleic acid drug development
Customers
  • Pharmaceutical Manufacturers
  • Research Institutions
  • Biotech Ventures
  • Pharmaceutical Development Partners
Products
  • Nucleic Acid Drug Technology
  • New Drug Discovery Compounds
  • Clinical Development Support

Raw Materials and Intermediates Supply

Overview
Provides high-quality pharmaceutical raw materials and food additives.
Competitiveness
Strict quality control system
Customers
  • Pharmaceutical Companies
  • Chemical Manufacturers
  • Health Food Raw Material Manufacturers
Products
  • Pharmaceutical Raw Materials
  • Intermediate Chemicals
  • Food Additives

Overseas Base Market Development

Overview
Expanding market development centered on bases in the US, China, and Europe.
Competitiveness
Global sales network
Customers
  • Local Pharmaceutical Wholesalers
  • Medical Institutions
  • Local Sales Agents
Products
  • General Medical Pharmaceuticals
  • Functional Foods

Competitive Advantage

Strengths

  • Established market position in urological pharmaceuticals
  • Strength in nucleic acid drug research and development
  • Stable financial base and capital strength
  • Global sales network
  • Diverse product lineup
  • Expansion into functional foods
  • Abundant specialized research labs and factory facilities
  • Long history and trusted brand
  • Support from diverse related subsidiaries
  • Response to rare disease areas through technological strength

Competitive Advantages

  • Clear strengths with specialization in urological pharmaceuticals
  • Advancing advanced technology development in nucleic acid drugs
  • Global market entry through overseas bases
  • Revenue stability ensured by diversified business
  • Quality maintenance through advanced R&D capabilities and facilities
  • Acquiring diverse customer base through functional food market entry
  • Comprehensive sales and distribution channels
  • Collaboration with major pharmaceutical companies to strengthen competitiveness
  • Trust gained through long-term brand building
  • High financial stability with ample capital and net assets

Threats

  • Intense market competition with competitors
  • High costs and long periods for new drug development
  • Challenges in approval due to strengthened regulations
  • Political and economic risks in overseas markets
  • Impact of drug price revisions and changes in insurance system
  • Need to respond to speed of technological innovation
  • Risk of revenue decline due to patent expiration
  • Instability in raw material costs
  • Changes in social conditions such as new infectious diseases
  • Demands for strengthened legal compliance and safety management

Innovations

2023: Strengthening Nucleic Acid Drug R&D

Overview
Advancing nucleic acid drug technology development and expanding treatments for rare diseases.
Impact
Contributes to accelerating rare disease drug development and market expansion.

2022: Completion of High Potency Solid Formulation Building at Odawara Comprehensive Formulation Factory

Overview
Strengthened manufacturing system for high-function solid formulations to improve productivity.
Impact
Achieved improved production efficiency and product diversification.

2021: Expansion of International Base Network

Overview
Established new pharmaceutical and technology bases in Beijing and Tianjin, China.
Impact
Strengthened competitiveness in Asian markets and accelerated local development.

2020: Introduction of New Compound Discovery Technology at Drug Discovery Lab

Overview
Adopted AI analysis-based compound discovery technology to improve drug discovery efficiency.
Impact
Shortened R&D periods and improved success rates.

Sustainability

  • Reducing environmental impact in pharmaceutical manufacturing processes
  • Promoting community safety consideration activities
  • Promoting waste recycling
  • Expanding introduction of renewable energy
  • Strengthening safety management systems and thorough employee training